Ngm Biopharmaceuticals (NASDAQ: NGM)
Some price data may be temporarily unavailable.
Ngm Biopharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ngm Biopharmaceuticals Company Info
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
News & Analysis
Is Good News Enough for You to Buy NGM on the Dip?
A drop in the overall market provides an opportunity for investors to pounce.
Why NGM Biopharmaceuticals Dived by 41% on Monday
The results of a hepatitis drug candidate's clinical trial were not good.
NGM Biopharmaceuticals Reports a Successful NASH Trial
Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.
Here's Why NGM Biopharmaceuticals Is Soaring Today
Shares popped after the clinical-stage biotech reported upbeat clinical results.
Why Aurora Cannabis, Sorrento Therapeutics, and NGM Biopharmaceuticals Slumped Today
Tough industry conditions and company-specific issues hit these stocks.
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.